The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.
Actavis is continuing to pursue a plan to buy Irish drug maker Warner Chilcott, as the U.S.-based company announced Tuesday its total number of shares and share-purchase options in order to comply with Ireland's merger-and-acquisition rules.
Healthcare analytics firm IMS Health has acquired social media analytics company Semantelli Corp., saying the purchase would allow it to provide real-time monitoring and delivery of insights into consumer and physician behavior and sentiments.
It's official. During its most recent quarterly conference call with analysts, CVS Caremark revealed what many had anticipated: Its acquisition of privately held Brazilian drug store chain Drogaria Onofre was complete.
Target has purchased two online retailers of cooking equipment in a move designed to expand its cooking and kitchenware business, said the mass merchandise retailer, which has lately made major investments in multichannel retailing.